Heterozygous Familial Hypercholesterolemia (HeFH)Phase 3NCT07450378
QLC7401 in Participants With Heterozygous Familial Hypercholesterolemia (HeFH)
A Phase 3 study testing QLC7401 Injection in people with Heterozygous Familial Hypercholesterolemia (HeFH), run by Qilu Pharmaceutical Co., Ltd..
Trial summary
This Phase III clinical trial aims to assess the efficacy and safety of QLC7401 Treatment in adults with Heterozygous Familial Hypercholesterolemia on a stable lipid-lowering therapy. Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Heterozygous Familial Hypercholesterolemia (HeFH)
- What is being tested?
- QLC7401 Injection
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 120 participants
- Where
- No sites listed yet
- Study dates
- May 2026to Jul 2028
- Phase
- Phase 3
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Aged 18-80 years (inclusive)
- Participants diagnosed with heterozygous familial hypercholesterolemia by Dutch Lipid Clinic
- Network criteria or genetic testing;
- Serum low density lipoprotein cholesterol ≥2.6 millimoles (mmol)/liter (L) at screening.
- Fasting triglyceride <4.5 mmol/L at screening.
- Participants on lipid-lowering therapies should be on a stable dose for ≥4 weeks before screening with no planned medication or dose change during study participation.
- Estimated glomerular filtration Rate (eGFR) >30 mL/min/1.73 m².
- Willing to provide informed consent.
Who cannot join
- New York Heart Association (NYHA) class III or IV heart failure.
- Uncontrolled cardiac arrhythmia.
- Cardiovascular Diseases within 3 months.
- Uncontrolled hypertension.
- Poorly controlled type 2 diabetes.
- Significant liver or kidney disease.
- Pregnancy or lactation.
- Other conditions deemed unsuitable by investigator.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Evaluation of Efficacy and Safety of QLC7401 in Participants With Heterozygous Familial Hypercholesterolemia on a Stable Lipid-lowering Therapy: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study
This Phase III clinical trial aims to assess the efficacy and safety of QLC7401 Treatment in adults with Heterozygous Familial Hypercholesterolemia on a stable lipid-lowering therapy. Participants will be randomly assigned to receive subcutaneous injections of either QLC7401 or a placebo according to the study schedule.
- Being tested
- QLC7401 Injection, Placebo
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
QLC7401 InjectionDrug
QLC7401 is a small interfering RNA (siRNA) targeting PCSK9. Administered as subcutaneous injection at a specified dose level.
PlaceboDrug
Placebo matching QLC7401 in appearance and administration.
| Study group | Role | What they receive |
|---|---|---|
| QLC7401 Injection | Experimental | Not described Receives: Drug: QLC7401 Injection |
| Placebo | Placebo comparator | Not described Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percent Change in LDL-C from Baseline
Measured: From baseline to Day 360
Secondary outcomes (1)
Incidence of Treatment-Emergent Adverse Events
Measured: From baseline to Day 360
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Mar 2026
- Study startMay 2026 (estimated)
- Primary completionApr 2028 (estimated)
- Study completionJul 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Heterozygous Familial Hypercholesterolemia (HeFH)Studies of the same condition, open and under way.
- More trials run by Qilu Pharmaceutical Co., Ltd.The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 120 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Qilu Pharmaceutical Co., Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07450378
- Sponsor's protocol ID
- QLC7401-304
- Status last verified
- Feb 2026
- First submitted
- 27 Feb 2026
- Last updated
- 4 Mar 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No